{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:15:36Z","timestamp":1793697336888,"version":"4.5.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41591-025-03630-w","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T05:03:55Z","timestamp":1744347835000},"page":"1969-1975","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3335-369X","authenticated-orcid":false,"given":"Yongmei","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7005-0842","authenticated-orcid":false,"given":"Xiaojia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-5780","authenticated-orcid":false,"given":"Shusen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuee","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengkui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyou","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yina","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesha","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-337X","authenticated-orcid":false,"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"3630_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1470-2045(07)70074-8","volume":"8","author":"S Cleator","year":"2007","unstructured":"Cleator, S., Heller, W. & Coombes, R. C. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 8, 235\u2013244 (2007).","journal-title":"Lancet Oncol."},{"key":"3630_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00512-7","volume":"9","author":"SR Stecklein","year":"2023","unstructured":"Stecklein, S. R. et al. ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. NPJ Breast Cancer 9, 10 (2023).","journal-title":"NPJ Breast Cancer"},{"key":"3630_CR3","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre, R. A. & Goetz, M. P. Advances in systemic therapies for triple negative breast cancer. BMJ 381, e071674 (2023).","journal-title":"BMJ"},{"key":"3630_CR4","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938\u20131948 (2010).","journal-title":"N. Engl. J. Med."},{"key":"3630_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10549-020-05867-0","volume":"184","author":"S Kazmi","year":"2020","unstructured":"Kazmi, S., Chatterjee, D., Raju, D., Hauser, R. & Kaufman, P. A. Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine. Breast Cancer Res. Treat. 184, 559\u2013565 (2020).","journal-title":"Breast Cancer Res. Treat."},{"key":"3630_CR6","doi-asserted-by":"crossref","unstructured":"O\u2019Shaughnessy, J. et al. Assessment of sacituzumab govitecan (SG) versus treatment of physician\u2019s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC). J. Clin. Oncol. 39, 1077-1077 (2021).","DOI":"10.1200\/JCO.2021.39.15_suppl.1077"},{"key":"3630_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3630_CR8","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1177\/1060028020966548","volume":"55","author":"JM Seligson","year":"2021","unstructured":"Seligson, J. M., Patron, A. M., Berger, M. J., Harvey, R. D. & Seligson, N. D. Sacituzumab govitecan-hziy: an antibody-drug conjugate for the treatment of refractory, metastatic, triple-negative breast cancer. Ann. Pharmacother. 55, 921\u2013931 (2021).","journal-title":"Ann. Pharmacother."},{"key":"3630_CR9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia, A. et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med. 384, 1529\u20131541 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3630_CR10","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1200\/JCO.23.01409","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia, A. et al. Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J. Clin. Oncol. 42, 1738\u20131744 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3630_CR11","doi-asserted-by":"publisher","first-page":"S585","DOI":"10.1016\/j.annonc.2021.08.1036","volume":"32","author":"J Rodon","year":"2021","unstructured":"Rodon, J. et al. 514O An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors. Ann. Oncol. 32, S585 (2021).","journal-title":"Ann. Oncol."},{"key":"3630_CR12","doi-asserted-by":"publisher","unstructured":"Yin, Y. M. et al. Efficacy and safety of SKB264 for previously treated metastatic triple negative breast cancer in phase 2 study. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-OT1-03-02 (2023).","DOI":"10.1158\/1538-7445.SABCS22-OT1-03-02"},{"key":"3630_CR13","doi-asserted-by":"publisher","unstructured":"Yin, Y. M. et al. Abstract PS08-08: Updated efficacy and safety of SKB264 (MK-2870) for previously treated metastatic triple negative breast cancer (mTNBC) in phase 2 study. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.SABCS23-PS08-08 (2024).","DOI":"10.1158\/1538-7445.SABCS23-PS08-08"},{"key":"3630_CR14","doi-asserted-by":"publisher","first-page":"951589","DOI":"10.3389\/fonc.2022.951589","volume":"12","author":"Y Cheng","year":"2022","unstructured":"Cheng, Y. et al. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. Front. Oncol. 12, 951589 (2022).","journal-title":"Front. Oncol."},{"key":"3630_CR15","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1016\/j.annonc.2023.09.557","volume":"34","author":"Q Ouyang","year":"2023","unstructured":"Ouyang, Q. et al. 380MO - SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)\/HER2-negative metastatic breast cancer (mBC): results from a phase I\/II, single-arm, basket trial. Ann. Oncol. 34, S337 (2023).","journal-title":"Ann. Oncol."},{"key":"3630_CR16","doi-asserted-by":"crossref","unstructured":"Fang, W. F. et al. SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: efficacy and safety data from a phase 2 study. J. Clin. Oncol. 41, 9114-9114 (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.9114"},{"key":"3630_CR17","doi-asserted-by":"publisher","unstructured":"Rodon, J. et al. Abstract CT038: Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a phase 2 study. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.am2024-ct038 (2024).","DOI":"10.1158\/1538-7445.am2024-ct038"},{"key":"3630_CR18","doi-asserted-by":"publisher","first-page":"V859","DOI":"10.1093\/annonc\/mdz394.010","volume":"30","author":"J Cort\u00e9s","year":"2019","unstructured":"Cort\u00e9s, J. et al. KEYNOTE-119: phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Ann. Oncol. 30, V859\u2013V860 (2019).","journal-title":"Ann. Oncol."},{"key":"3630_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","volume":"57","author":"KA Won","year":"2020","unstructured":"Won, K. A. & Spruck, C. Triple\u2011negative breast cancer therapy: current and future perspectives (Review). Int. J. Oncol. 57, 1245\u20131261 (2020).","journal-title":"Int. J. Oncol."},{"key":"3630_CR20","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s12325-020-01613-6","volume":"38","author":"SS Mougalian","year":"2021","unstructured":"Mougalian, S. S., Kish, J. K., Zhang, J., Liassou, D. & Feinberg, B. A. Effectiveness of eribulin in metastatic breast cancer: 10 years of real-world clinical experience in the United States. Adv. Ther. 38, 2213\u20132225 (2021).","journal-title":"Adv. Ther."},{"key":"3630_CR21","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1016\/j.annonc.2022.03.185","volume":"33","author":"P Schmid","year":"2022","unstructured":"Schmid, P. et al. 166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): initial results from BEGONIA, a phase Ib\/II study. Ann. Oncol. 33, S199 (2022).","journal-title":"Ann. Oncol."},{"key":"3630_CR22","doi-asserted-by":"publisher","first-page":"103203","DOI":"10.1016\/j.esmoop.2024.103203","volume":"9","author":"P Schmid","year":"2024","unstructured":"Schmid, P. et al. 181O Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: a phase Ib\/II study of multiple treatment (tx) combinations in pts with locally advanced\/metastatic BC (LA\/mBC). ESMO Open 9, 103203 (2024).","journal-title":"ESMO Open"},{"key":"3630_CR23","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia, A. et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann. Oncol. 32, 1148\u20131156 (2021).","journal-title":"Ann. Oncol."},{"key":"3630_CR24","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med. 386, 1143\u20131154 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3630_CR25","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9, F. et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401, 1773\u20131785 (2023).","journal-title":"Lancet"},{"key":"3630_CR26","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","volume":"35","author":"C Saura","year":"2024","unstructured":"Saura, C. et al. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Ann. Oncol. 35, 302\u2013307 (2024).","journal-title":"Ann. Oncol."},{"key":"3630_CR27","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N. Engl. J. Med. 384, 1125\u20131135 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3630_CR28","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/ijc.34424","volume":"152","author":"B Xu","year":"2023","unstructured":"Xu, B. et al. A phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. Int. J. Cancer 152, 2134\u20132144 (2023).","journal-title":"Int. J. Cancer"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03630-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03630-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03630-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:10:54Z","timestamp":1776856254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03630-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3630"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03630-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"27 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.X. has served as advisor or consultant for Novartis and AstraZeneca. J.G., X.J., Y.D. and G.L. are employees of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}